Table 1.

Diagnostic criteria for cardiotoxicity.

Society	Diagnostic Criteria of Cardiotoxicity	Year of Publication
ASE/EACVI	Decrease in LVEF of >10%, to LVEF < 53% Relative drop in GLS > 15% from baseline suggests subclinical LV dysfunction	2014 [14]
ESC	Decrease in LVEF of >10% from baseline, to LVEF < 50% Decrease in GLS of >15% from baseline may suggest risk of cardiotoxicity	2016 [7]
ESMO	LVEF drop by ≥10–15%, or to <50% Symptomatic heart failure regardless of LVEF	2020 [13]
IC-OS	For asymptomatic patients: Mild: LVEF ≥ 50% and new relative decrease in GLS by >15% from baseline, and/or new rise in cardiac biomarkers (cardiac troponin I/T > 99th percentile, BNP > 35 pg/mL, NT-proBNP ≥ 125 pg/mL). New reduction in LVEF by ≥10% or <10%, to absolute 40% < LVEF < 50%, and new relative decrease in GLS by >15% from baseline, and/or new rise in cardiac biomarkers. Severe: new LVEF reduction to <40%. For symptomatic patients: mild heart failure symptoms or more.	2021 [15]

ASE = American Society of Echocardiography; EACVI = European Association of Cardiovascular Imaging; ESC = European Society of Cardiology; ESMO = European Society of Cardiology; IC-OS = International Cardio-Oncology Society; LVEF = left ventricular ejection fraction; GLS = global longitudinal strain; BNP = B-type natriuretic peptide; NT-proBNP = N-terminal pro-BNP.